Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBNX NASDAQ:EMBC NASDAQ:IRMD NASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$22.26+8.6%$19.21$8.89▼$26.66$967.64MN/A1.17 million shs568,463 shsEMBCEmbecta$14.32+0.4%$13.58$9.20▼$21.48$837.51M1.1529,462 shs374,956 shsIRMDiRadimed$71.24+0.2%$70.00$46.86▼$74.43$906.17M1.0249,686 shs30,650 shsTLSITriSalus Life Sciences$4.62+2.2%$4.63$3.42▼$5.88$230.39M0.47122,175 shs95,649 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics0.00%+13.98%+10.20%+66.12%+2,225,999,900.00%EMBCEmbecta0.00%+3.02%-4.28%+42.77%+6.00%IRMDiRadimed0.00%+1.38%-1.04%+20.70%+42.99%TLSITriSalus Life Sciences0.00%-1.70%-7.41%-6.85%+1.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$22.26+8.6%$19.21$8.89▼$26.66$967.64MN/A1.17 million shs568,463 shsEMBCEmbecta$14.32+0.4%$13.58$9.20▼$21.48$837.51M1.1529,462 shs374,956 shsIRMDiRadimed$71.24+0.2%$70.00$46.86▼$74.43$906.17M1.0249,686 shs30,650 shsTLSITriSalus Life Sciences$4.62+2.2%$4.63$3.42▼$5.88$230.39M0.47122,175 shs95,649 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics0.00%+13.98%+10.20%+66.12%+2,225,999,900.00%EMBCEmbecta0.00%+3.02%-4.28%+42.77%+6.00%IRMDiRadimed0.00%+1.38%-1.04%+20.70%+42.99%TLSITriSalus Life Sciences0.00%-1.70%-7.41%-6.85%+1.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBNXBeta Bionics 2.69Moderate Buy$24.449.81% UpsideEMBCEmbecta 2.60Moderate Buy$19.0032.68% UpsideIRMDiRadimed 3.00Buy$72.001.07% UpsideTLSITriSalus Life Sciences 3.00Buy$10.90135.93% UpsideCurrent Analyst Ratings BreakdownLatest TLSI, IRMD, BBNX, and EMBC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/1/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral ➝ Buy$18.00 ➝ $26.0010/1/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$18.00 ➝ $26.009/27/2025BBNXBeta BionicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025EMBCEmbectaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025IRMDiRadimedWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B-)9/27/2025TLSITriSalus Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/22/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $28.009/5/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/26/2025EMBCEmbectaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/30/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $21.007/30/2025BBNXBeta BionicsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral$15.00 ➝ $17.00(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBNXBeta Bionics$65.12M14.86N/AN/A($5.72) per share-3.89EMBCEmbecta$1.10B0.76$3.34 per share4.29($12.80) per share-1.12IRMDiRadimed$73.24M12.37$1.58 per share45.03$6.85 per share10.40TLSITriSalus Life Sciences$35.99M6.40N/AN/A($0.83) per share-5.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBNXBeta Bionics-$54.76MN/A0.00∞N/AN/AN/AN/AN/AEMBCEmbecta$78.30M$1.4310.014.660.797.58%-23.40%14.46%11/25/2025 (Estimated)IRMDiRadimed$19.23M$1.6243.9835.62N/A26.61%23.30%20.62%10/30/2025 (Estimated)TLSITriSalus Life Sciences-$30.05M-$1.18N/AN/AN/A-86.61%N/A-116.50%11/13/2025 (Estimated)Latest TLSI, IRMD, BBNX, and EMBC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025IRMDiRadimed$0.43N/AN/AN/A$20.50 millionN/A8/12/2025Q2 2025TLSITriSalus Life Sciences-$0.22-$0.27-$0.05-$0.27$10.69 million$11.21 million8/8/2025Q3 2025EMBCEmbecta$0.7720$1.12+$0.3480$0.78$278.15 million$295.50 million7/29/2025Q2 2025BBNXBeta Bionics-$0.51-$0.39+$0.12-$0.39$19.73 million$23.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBNXBeta BionicsN/AN/AN/AN/AN/AEMBCEmbecta$0.604.19%N/A41.96%N/AIRMDiRadimed$0.680.95%N/A41.98%1 YearsTLSITriSalus Life SciencesN/AN/AN/AN/AN/ALatest TLSI, IRMD, BBNX, and EMBC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/6/2025EMBCEmbectaquarterly$0.154.14%8/29/20258/29/20259/15/20257/31/2025IRMDiRadimedquarterly$0.171.13%8/18/20258/18/20258/28/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBNXBeta BionicsN/A14.6813.79EMBCEmbectaN/A2.471.78IRMDiRadimedN/A8.787.51TLSITriSalus Life SciencesN/A4.083.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBNXBeta BionicsN/AEMBCEmbecta93.83%IRMDiRadimed92.34%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipBBNXBeta BionicsN/AEMBCEmbecta0.42%IRMDiRadimed36.80%TLSITriSalus Life Sciences27.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBNXBeta Bionics29443.47 millionN/AN/AEMBCEmbecta2,10058.49 million58.24 millionOptionableIRMDiRadimed11012.72 million8.04 millionOptionableTLSITriSalus Life Sciences10649.87 million36.15 millionNot OptionableTLSI, IRMD, BBNX, and EMBC HeadlinesRecent News About These CompaniesTriSalus Life Sciences (NASDAQ:TLSI) Cut to "Sell" at Wall Street ZenSeptember 28, 2025 | americanbankingnews.comTriSalus Life Sciences (NASDAQ:TLSI) Lowered to Sell Rating by Wall Street ZenSeptember 28, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Recommendation of "Buy" by AnalystsSeptember 20, 2025 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Raised to Hold at Wall Street ZenSeptember 20, 2025 | marketbeat.comTriSalus Life Sciences Reports Strong Growth Amid ChallengesAugust 14, 2025 | msn.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comTriSalus Life Sciences Reports Strong Q2 2025 GrowthAugust 13, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comTriSalus Life Sciences backs FY25 revenue growth view up 50%August 12, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue EstimatesAugust 12, 2025 | zacks.comTriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth ConferenceJuly 30, 2025 | businesswire.comTriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference CallJuly 29, 2025 | businesswire.comTriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred StockJuly 24, 2025 | businesswire.comTriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System - Business WireJune 25, 2025 | businesswire.comTriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital StructureJune 23, 2025 | businesswire.comTriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. PatienceMay 30, 2025 | businesswire.comJodi Devlin Sells 4,764 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockMay 22, 2025 | insidertrades.comTriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable marketMay 15, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comTriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 GuidanceMay 15, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLSI, IRMD, BBNX, and EMBC Company DescriptionsBeta Bionics NASDAQ:BBNX$22.26 +1.77 (+8.64%) As of 10/3/2025 04:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Embecta NASDAQ:EMBC$14.32 +0.06 (+0.42%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$14.55 +0.23 (+1.63%) As of 07:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.iRadimed NASDAQ:IRMD$71.24 +0.16 (+0.23%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$71.15 -0.09 (-0.13%) As of 10/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.TriSalus Life Sciences NASDAQ:TLSI$4.62 +0.10 (+2.21%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$4.62 +0.00 (+0.11%) As of 10/3/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
